TES-4207 / TES Pharma - LARVOL DELTA

TES-4207, a first-in-class antagonist of the immune checkpoint NR2F6, drives anti-tumor immunity and enhances efficacy of PD-1 blockade (ESMO-IO 2025) - "These results suggest that targeting NR2F6 with TES-4207 could increase patient sensitivity to ICI therapy, particularly in those with limited response. Further preclinical development and combination studies are ongoing.Legal entity responsible for the study The authors."

Clinical • IO biomarker • Melanoma • Oncology • Solid Tumor • CD8 • IFNG • IL2

First-in-class NR2F6 antagonist TES-ONC-07 enhances anti-cancer host immunity reducing tumor growth in a "cold" cancer model (AACR 2025) - "Potentially, treatment with TES-ONC-07 may increase sensitivity to ICI, also in those patients with limited response. Further studies are ongoing to test combination therapies as well as complete the preclinical development of TES-ONC-07."

IO biomarker • Preclinical • Melanoma • Oncology • Solid Tumor • CD4 • CD8 • IFNG • IL2